【摘要】 目的:探讨吉非替尼对不同性别晚期非小细胞肺癌(NSCLC)患者的疗效和安全性。方法:选择化疗失败的晚期NSCLC患者74例,分为女性组(36例)和男性组(38例),应用吉非替尼进行单药治疗,口服剂量为250 mg/d。分析两组治疗疗效和安全性。结果:女性组和男性组的总有效率(47.2%vs 26.3%,P=0.062)以及中位无进展生存期(7.9个月vs 5.7个月,P=0.093)差异均无统计学意义;而其中女性腺癌患者的有效率(53.8%)与以及中位无进展生存期(10.1个月)明显优于男性鳞癌患者,差异均有统计学意义,P值均<0.05。两组的不良反应相似主要为皮疹和腹泻。结论:对于晚期NSCLC患者,在无检测表皮生长因子受体(EGFR)情况下,合理选择优势人群,应用分子靶向药物吉非替尼治疗,疗效较高,能有助于提高NSCLC临床个体化治疗水平。更多还原

【Abstract】 OBJECTIVE:To select dominant crowd in advanced non-small-cell lung cancer(NSCLC) by comparing the efficacy and safety of gefitinib on advanced NSCLC in different gender groups.METHODS: Seventy-four advanced NSCLC patients(36 female and 38 male) who failed in previous chemotherapy perorally received gefitinib 250 mg/d.The efficacy and safety of gefitinib on advanced NSCLC between the two groups was compared.RESULTS: Neither the overall response rate(47.2% vs 26.3%,P=0.062) nor the median progression free survival(7.9 months vs 5.7 months,P=0.093) between the female and male patients indicated any significant difference.However,the overall response rate(53.8%) as well as the median progression-free survival(10.1 months) were significantly higher in the female patients with adenocarcinoma than that in the male patients with squamous carcinoma(P<0.05).The main toxicities were skin rash and diarrhea which was similar in the two groups.CONCLUSION: If EGFR has not been detected yet,rational selection of dominant crowd and well-planned treatment with gefitinib will be rewarding to enhance individualized therapy in NSCLC.更多还原